Review



assays id screen influenza a antibody multi species elisa kits idvet  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Sino Biological assays id screen influenza a antibody multi species elisa kits idvet
    Assays Id Screen Influenza A Antibody Multi Species Elisa Kits Idvet, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/h3n2/Influenza+A+H3N2+(A%2Fswine%2FChina%2FJG20%2F2019)+Neuraminidase+%2F+NA/10__1016_slash_j__isci__2026__115743-616-140-135
    Average 94 stars, based on 1 article reviews
    assays id screen influenza a antibody multi species elisa kits idvet - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Vaccine molecules
    Article Snippet: .. Serum ELISA ELISA 96-well plates (Costar 3590) were coated with one of the following recombinant influenza HA proteins: A/Puerto Rico/8/1934 (H1N1) (11684-VO8H, Sino Biological), A/Hong Kong/483/97 (H5N1) (11689-VO8H, Sino Biological), A/northern shoveler/California/HKWF115/07 (H6N1) (MBS434125 MyBioSource, CA, US, or 11723-V08H, Sino Biological), A/pintail duck/Alberta/114/1979 (H8N4) (11722-V08H, Sino Biological), A/Hong Kong/1073/99 (H9N2) (11229-V08H, Sino Biological), A/duck/Yangzhou/906/2002 (H11N2) (11705-V08H, Sino Biological), A/black-headed gull/Netherlands/1/00 (H13N8) (11721-V08H, Sino Biological), A/Shanghai/1/2013 (H7N9) (40104-V08B, Sino Biological), or A/Hong Kong/1/1968 (H3N2) (40116-V08B, Sino Biological). .. Alternatively, plates were coated with inactivated virus: A/Puerto Rico/8/1934 (H1N1) (Charles River, MA, US) (1:1600), or A/California/7/2009 (H1N1) (Pandemrix, GlaxoSmithKline, Brentford, UK) (1:50).

    Recombinant:

    Article Title: Vaccine molecules
    Article Snippet: .. Serum ELISA ELISA 96-well plates (Costar 3590) were coated with one of the following recombinant influenza HA proteins: A/Puerto Rico/8/1934 (H1N1) (11684-VO8H, Sino Biological), A/Hong Kong/483/97 (H5N1) (11689-VO8H, Sino Biological), A/northern shoveler/California/HKWF115/07 (H6N1) (MBS434125 MyBioSource, CA, US, or 11723-V08H, Sino Biological), A/pintail duck/Alberta/114/1979 (H8N4) (11722-V08H, Sino Biological), A/Hong Kong/1073/99 (H9N2) (11229-V08H, Sino Biological), A/duck/Yangzhou/906/2002 (H11N2) (11705-V08H, Sino Biological), A/black-headed gull/Netherlands/1/00 (H13N8) (11721-V08H, Sino Biological), A/Shanghai/1/2013 (H7N9) (40104-V08B, Sino Biological), or A/Hong Kong/1/1968 (H3N2) (40116-V08B, Sino Biological). .. Alternatively, plates were coated with inactivated virus: A/Puerto Rico/8/1934 (H1N1) (Charles River, MA, US) (1:1600), or A/California/7/2009 (H1N1) (Pandemrix, GlaxoSmithKline, Brentford, UK) (1:50).

    Article Title: A Zanamivir-protein conjugate mimicking mucin for trapping influenza virion particles and inhibiting neuraminidase activity.
    Article Snippet: Influenza viruses contribute significantly to the global health burden, necessitating the development of strategies against transmission as well as effective antiviral treatments.. The present study reports a biomimetic strategy inspired by the natural antiviral properties of mucins.. A bovine serum albumin (BSA) conjugate decorated with the multivalent neuraminidase inhibitor Zanamivir (ZA-BSA) was synthesized using copper-free click chemistry.

    Article Title: Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine
    Article Snippet: .. 96 well Nunc TM MaxiSorp TM plates were separately coated with 50μL/well of 2μg/mL (for tIgG and IgG subclass detection) or 5μg/mL (for IgA and IgM detection) recombinant Influenza A H1N1 (A/Puerto Rico/8/34/Mount Sinai) Nucleoprotein/NP I116M (ECD, His Tag), Influenza A H1N1 (A/Puerto Rico/8/34/Mount Sinai) Matrix protein 1 / M1 Protein (His Tag), Influenza A H3N2 (A/Hong Kong/2671/2019) Nucleoprotein / NP Protein (His Tag) Influenza A H3N2 (A/Aichi/2/1968) Matrix protein 1 / M1 Protein (His Tag) or Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein/RSV-F protein (ECD, His Tag) (all SinoBiological), overnight at 4 °C. .. Plates were then washed with PBS/Tween (0.05% v/v), and then blocked for 1 hour at RT with Blocker Casein in PBS (Thermo Fisher Scientific).

    Article Title: mRNA-based influenza vaccine expands breadth of B cell response in humans
    Article Snippet: Recombinant HA was biotinylated using the EZ-Link Micro NHS-PEG4-Biotinylation Kit (Thermo Scientific); excess biotin was removed using 7-kDa Zeba desalting columns (Pierce). .. For biolayer interferometry (BLI), recombinant 6x His-tagged HA proteins from influenza strains (A/Wisconsin/588/2019, A/Darwin/6/2021, B/Phuket/3073/2013, B/Austria/1359417/2021) expressed in 293F cells were purchased from Immune Technology Corp. For Ig-Seq, recombinant 6x His-tagged HA protein from H3N2 (A/Darwin/6/2021) expressed in 293F cells was purchased from SinoBiological. .. For multiplex fluorescent bead assay, 293F-expressed recombinant HA proteins from the following influenza strains were purchased from Immune Technology Corp: H3N2 strains, A/Thailand/8/2022, A/Darwin/6/2021, A/Cambodia/e0826360/2020, A/South Australia/34/2019, A/Hong Kong/2671/2019, A/Singapore/INFIMH-16-0019/2016, A/Switzerland/8060/2017, A/Victoria/361/2011, A/Brisbane/10/2007; H1N1 strains, A/Wisconsin/67/2022, A/Sydney/5/2021, A/Wisconsin/588/2019, A/Guangdong-Maonan/SWL1536/2019, A/Michigan/45/2015, A/California/04/2009, A/Puerto_Rico/8/1934.

    Article Title: Intranasal vaccine induces broad and long-lasting immunity against the hemagglutinin stem of group 2 influenza A viruses.
    Article Snippet: .. Briefly, 96-well plates were coated with 100 μl/well of recombinant influenza A H3N2 (A/Texas/50/2012) hemagglutinin (Sino Biological Inc.) at 0.5 μg/ml and incubated overnight at 4 ◦C. ..

    SPR Assay:

    Article Title: A Zanamivir-protein conjugate mimicking mucin for trapping influenza virion particles and inhibiting neuraminidase activity.
    Article Snippet: Influenza viruses contribute significantly to the global health burden, necessitating the development of strategies against transmission as well as effective antiviral treatments.. The present study reports a biomimetic strategy inspired by the natural antiviral properties of mucins.. A bovine serum albumin (BSA) conjugate decorated with the multivalent neuraminidase inhibitor Zanamivir (ZA-BSA) was synthesized using copper-free click chemistry.

    Mutagenesis:

    Article Title: A Zanamivir-protein conjugate mimicking mucin for trapping influenza virion particles and inhibiting neuraminidase activity.
    Article Snippet: Influenza viruses contribute significantly to the global health burden, necessitating the development of strategies against transmission as well as effective antiviral treatments.. The present study reports a biomimetic strategy inspired by the natural antiviral properties of mucins.. A bovine serum albumin (BSA) conjugate decorated with the multivalent neuraminidase inhibitor Zanamivir (ZA-BSA) was synthesized using copper-free click chemistry.

    Virus:

    Article Title: Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine
    Article Snippet: .. 96 well Nunc TM MaxiSorp TM plates were separately coated with 50μL/well of 2μg/mL (for tIgG and IgG subclass detection) or 5μg/mL (for IgA and IgM detection) recombinant Influenza A H1N1 (A/Puerto Rico/8/34/Mount Sinai) Nucleoprotein/NP I116M (ECD, His Tag), Influenza A H1N1 (A/Puerto Rico/8/34/Mount Sinai) Matrix protein 1 / M1 Protein (His Tag), Influenza A H3N2 (A/Hong Kong/2671/2019) Nucleoprotein / NP Protein (His Tag) Influenza A H3N2 (A/Aichi/2/1968) Matrix protein 1 / M1 Protein (His Tag) or Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein/RSV-F protein (ECD, His Tag) (all SinoBiological), overnight at 4 °C. .. Plates were then washed with PBS/Tween (0.05% v/v), and then blocked for 1 hour at RT with Blocker Casein in PBS (Thermo Fisher Scientific).

    Article Title: Chronic lymphocytic leukemia specificity analyses unveil bacterial lipopolysaccharides as the cognate ligands of established stereotyped BCR subsets
    Article Snippet: .. Virology, Claireaux Nat.Comm.13(2022)4539 Tetanus Toxoid Creative Biolabs Antigens used in Antigen array Source West Nijl Virus (WNV) NS1 Immune Technology Japanese Encephalitis Virus (JEV) NS1 Immune Technology Tick-Borne Encephalitis Virus (TBEV) NS1 Immune Technology Usutu Virus (USUV) NS1 The native antigen company Yellow Fever Virus (YFV) NS1 Immune Technology Influenza Virus (Flu) H1N1 (2009) NP Sino Biological Influenza Virus (Flu) H7N9 (2013) NP Sino Biological Influenza Virus (Flu) H1N1 (A/California/04/2009) HA1 subunit Sino Biological Influenza Virus (Flu) H3N2 (A/Victoria/361/2011) HA1 subunit Sino Biological Corona Virus OC43 S1 Inhouse antigen obtained from Dr. Berend Jan Bosch, University of Utrecht Corona Virus NL63 S1 Inhouse antigen obtained from Dr. Berend Jan Bosch, University of Utrecht Corona Virus 229-E S1 Inhouse antigen obtained from Dr. Berend Jan Bosch, University of Utrecht Corona Virus HKU1 S1 Inhouse antigen obtained from Dr. Berend Jan Bosch, University of Utrecht Corona Virus SARS-CoV-2 S1 Inhouse antigen obtained from Dr. Berend Jan Bosch, University of Utrecht Corona Virus MERS S1 Inhouse antigen obtained from Dr. Bart Haagmans, Erasmus MC, Rotterdam Corona Virus SARS-CoV-1 S1 Inhouse antigen obtained from Dr. Berend Jan Bosch, University of Utrecht Respiratory Syncytial Virus (RSV) NP Sino Biological ..

    Incubation:

    Article Title: Intranasal vaccine induces broad and long-lasting immunity against the hemagglutinin stem of group 2 influenza A viruses.
    Article Snippet: .. Briefly, 96-well plates were coated with 100 μl/well of recombinant influenza A H3N2 (A/Texas/50/2012) hemagglutinin (Sino Biological Inc.) at 0.5 μg/ml and incubated overnight at 4 ◦C. ..



    Similar Products

    sequencing  (ATCC)
    94
    ATCC sequencing
    Sequencing, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/h3n2/Quantitative+Genomic+RNA+from+Influenza+A+virus+(H3N2)+strain+A%2FWisconsin%2F15%2F2009/pm42320401-34-8-13
    Average 94 stars, based on 1 article reviews
    sequencing - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    assays id screen influenza a antibody multi species elisa kits idvet  (Sino Biological)
    94
    Sino Biological assays id screen influenza a antibody multi species elisa kits idvet
    Assays Id Screen Influenza A Antibody Multi Species Elisa Kits Idvet, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/h3n2/Influenza+A+H3N2+(A%2Fswine%2FChina%2FJG20%2F2019)+Neuraminidase+%2F+NA/10__1016_slash_j__isci__2026__115743-616-140-135
    Average 94 stars, based on 1 article reviews
    assays id screen influenza a antibody multi species elisa kits idvet - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    iav h3n2 fukui infected cells  (Fukui Bank Ltd)
    86
    Fukui Bank Ltd iav h3n2 fukui infected cells
    Iav H3n2 Fukui Infected Cells, supplied by Fukui Bank Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/h3n2/fukui+h3n2+iav+infection/pmc13246656-105-17-18
    Average 86 stars, based on 1 article reviews
    iav h3n2 fukui infected cells - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    iav h3n2 fukui infection  (Fukui Bank Ltd)
    86
    Fukui Bank Ltd iav h3n2 fukui infection
    Effects of zapnometinib treatment and IAV infection on HLA-I surface expression in Calu-3 cells. Calu-3 cells were treated with zapnometinib and/or infected with IAV <t>H3N2/Fukui,</t> and HLA-I surface expression was analyzed using QIFIKIT-calibrated flow cytometry assay with the W6/32 monoclonal antibody (mAb) (pan-HLA class I specific for HLA-A, -B, and -C alleles). Untreated cells served as baseline for relative fold-change calculations. (A) Representative result of flow cytometry histograms showing HLA-I surface expression analysis (n=3). (B) Absolute quantification of HLA-I molecules on the surface of Calu-3 cells (C) Relative HLA-I surface expression normalized to untreated control (fold changes 1.01-1.13, Brown-Forsythe ANOVA with Dunnett’s T3 multiple comparisons test, all p>0.05). The statistical analysis was performed using Brown-Forsythe ANOVA with Dunnett’s T3 multiple comparisons correction. Flow cytometry data were analyzed using FlowJo software ver. 10.8 (FlowJo LLC, BD). Statistical analysis and visualization were performed using GraphPad Prism software ver. 9.3.
    Iav H3n2 Fukui Infection, supplied by Fukui Bank Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/h3n2/fukui+h3n2+iav+infection/pmc13246656-122-18-19
    Average 86 stars, based on 1 article reviews
    iav h3n2 fukui infection - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Effects of zapnometinib treatment and IAV infection on HLA-I surface expression in Calu-3 cells. Calu-3 cells were treated with zapnometinib and/or infected with IAV H3N2/Fukui, and HLA-I surface expression was analyzed using QIFIKIT-calibrated flow cytometry assay with the W6/32 monoclonal antibody (mAb) (pan-HLA class I specific for HLA-A, -B, and -C alleles). Untreated cells served as baseline for relative fold-change calculations. (A) Representative result of flow cytometry histograms showing HLA-I surface expression analysis (n=3). (B) Absolute quantification of HLA-I molecules on the surface of Calu-3 cells (C) Relative HLA-I surface expression normalized to untreated control (fold changes 1.01-1.13, Brown-Forsythe ANOVA with Dunnett’s T3 multiple comparisons test, all p>0.05). The statistical analysis was performed using Brown-Forsythe ANOVA with Dunnett’s T3 multiple comparisons correction. Flow cytometry data were analyzed using FlowJo software ver. 10.8 (FlowJo LLC, BD). Statistical analysis and visualization were performed using GraphPad Prism software ver. 9.3.

    Journal: Frontiers in Immunology

    Article Title: Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

    doi: 10.3389/fimmu.2026.1790267

    Figure Lengend Snippet: Effects of zapnometinib treatment and IAV infection on HLA-I surface expression in Calu-3 cells. Calu-3 cells were treated with zapnometinib and/or infected with IAV H3N2/Fukui, and HLA-I surface expression was analyzed using QIFIKIT-calibrated flow cytometry assay with the W6/32 monoclonal antibody (mAb) (pan-HLA class I specific for HLA-A, -B, and -C alleles). Untreated cells served as baseline for relative fold-change calculations. (A) Representative result of flow cytometry histograms showing HLA-I surface expression analysis (n=3). (B) Absolute quantification of HLA-I molecules on the surface of Calu-3 cells (C) Relative HLA-I surface expression normalized to untreated control (fold changes 1.01-1.13, Brown-Forsythe ANOVA with Dunnett’s T3 multiple comparisons test, all p>0.05). The statistical analysis was performed using Brown-Forsythe ANOVA with Dunnett’s T3 multiple comparisons correction. Flow cytometry data were analyzed using FlowJo software ver. 10.8 (FlowJo LLC, BD). Statistical analysis and visualization were performed using GraphPad Prism software ver. 9.3.

    Article Snippet: Comparisons with vehicle controls confirmed that zapnometinib treatment alone ( , middle), as well as combined treatment with IAV H3N2/Fukui infection, displayed similar patterns, with 3% of ligands upregulated and 6–8% downregulated ( , right).

    Techniques: Infection, Expressing, Flow Cytometry, Quantitative Proteomics, Control, Software

    Mass spectrometric profiling of the Calu-3 cells HLA-I immunopeptidome following zapnometinib treatment and IAV infection. Calu-3 cells were treated with zapnometinib and/or infected with IAV H3N2/Fukui and HLA-I–bound peptides were isolated and analyzed by LC-MS/MS. Peptides were defined as HLA-I ligands if the NetMHCpan prediction showed percentile rank or IC50 score below ≤2% and 500 nM respectively. (A) Total number of HLA-I ligands (blue bars) and corresponding source proteins (black bars) identified under each condition. Red triangles indicate the purity of identified ligands (the percent of predicted ligands among the total identified peptides. (B) HLA-I allotype distribution of predicted ligands in zapnometinib-treated cells and IAV-infected cells. (C) Venn diagram showing overlap of HLA-I identified ligands between each treatment condition and mock control. (D) HLA-I allotype distribution of exclusively identified ligands under each treatment. (E) Venn diagram showing overlap of source proteins for HLA-I ligands respective for each treatment and infection conditions. A comprehensive list of identified peptides used for generating the figure can be found in the . * Indicates statistical significance.

    Journal: Frontiers in Immunology

    Article Title: Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

    doi: 10.3389/fimmu.2026.1790267

    Figure Lengend Snippet: Mass spectrometric profiling of the Calu-3 cells HLA-I immunopeptidome following zapnometinib treatment and IAV infection. Calu-3 cells were treated with zapnometinib and/or infected with IAV H3N2/Fukui and HLA-I–bound peptides were isolated and analyzed by LC-MS/MS. Peptides were defined as HLA-I ligands if the NetMHCpan prediction showed percentile rank or IC50 score below ≤2% and 500 nM respectively. (A) Total number of HLA-I ligands (blue bars) and corresponding source proteins (black bars) identified under each condition. Red triangles indicate the purity of identified ligands (the percent of predicted ligands among the total identified peptides. (B) HLA-I allotype distribution of predicted ligands in zapnometinib-treated cells and IAV-infected cells. (C) Venn diagram showing overlap of HLA-I identified ligands between each treatment condition and mock control. (D) HLA-I allotype distribution of exclusively identified ligands under each treatment. (E) Venn diagram showing overlap of source proteins for HLA-I ligands respective for each treatment and infection conditions. A comprehensive list of identified peptides used for generating the figure can be found in the . * Indicates statistical significance.

    Article Snippet: Comparisons with vehicle controls confirmed that zapnometinib treatment alone ( , middle), as well as combined treatment with IAV H3N2/Fukui infection, displayed similar patterns, with 3% of ligands upregulated and 6–8% downregulated ( , right).

    Techniques: Infection, Isolation, Liquid Chromatography with Mass Spectroscopy, Control

    Qualitative and quantitative influence of zapnometinib treatment and IAV infection on the Calu-3 HLA-I peptidome. Calu-3 cells were treated with zapnometinib and/or infected with IAV H3N2/Fukui and HLA-I–bound peptides were isolated for LC-MS/MS analysis. (A) Volcano plots depicting the modulation and relative abundance of HLA-I identified ligands between the indicated conditions. Each point corresponds to an HLA-I ligand, the x-axis shows log2 fold change in relative abundance, and the y-axis indicates -log10 Benjamini–Hochberg corrected p-value. upregulated ligands (≥ 2-fold increase, adjusted p -value <0.05) are indicated in red and those significantly downregulated (≤-2-fold decrease, adjusted p < 0.05) are in blue. Percentages of significantly modulated ligands are indicated in the respective quadrants. (B) Distribution of HLA-I allotypes among the up- and downmodulated ligands. Data processing and visualization were performed in R (ver. 4.2) using in-house R scripts. A comprehensive list of identified peptides used for generating the figure can be found in the .

    Journal: Frontiers in Immunology

    Article Title: Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

    doi: 10.3389/fimmu.2026.1790267

    Figure Lengend Snippet: Qualitative and quantitative influence of zapnometinib treatment and IAV infection on the Calu-3 HLA-I peptidome. Calu-3 cells were treated with zapnometinib and/or infected with IAV H3N2/Fukui and HLA-I–bound peptides were isolated for LC-MS/MS analysis. (A) Volcano plots depicting the modulation and relative abundance of HLA-I identified ligands between the indicated conditions. Each point corresponds to an HLA-I ligand, the x-axis shows log2 fold change in relative abundance, and the y-axis indicates -log10 Benjamini–Hochberg corrected p-value. upregulated ligands (≥ 2-fold increase, adjusted p -value <0.05) are indicated in red and those significantly downregulated (≤-2-fold decrease, adjusted p < 0.05) are in blue. Percentages of significantly modulated ligands are indicated in the respective quadrants. (B) Distribution of HLA-I allotypes among the up- and downmodulated ligands. Data processing and visualization were performed in R (ver. 4.2) using in-house R scripts. A comprehensive list of identified peptides used for generating the figure can be found in the .

    Article Snippet: Comparisons with vehicle controls confirmed that zapnometinib treatment alone ( , middle), as well as combined treatment with IAV H3N2/Fukui infection, displayed similar patterns, with 3% of ligands upregulated and 6–8% downregulated ( , right).

    Techniques: Infection, Isolation, Liquid Chromatography with Mass Spectroscopy